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A B S T R A C T
Background: In 2019, Mexico became the first Latin American country committed to hepatitis C virus (HCV)
elimination, but the amount of intervention scale-up required is unclear. In Tijuana, HCV among people who
inject drugs (PWID) is high; yet there is minimal and intermittent harm reduction, and involuntary exposure to
compulsory abstinence programs (CAP) occurs which is associated with increased HCV risk. We determined
what combination intervention scale-up can achieve HCV elimination among current and former PWID in
Tijuana.
Methods: We constructed a dynamic, deterministic model of HCV transmission, disease progression, and harm
reduction among current and former PWID parameterized to Tijuana (~10,000 current PWID, 90% HCV ser-
opositive, minimal opiate agonist therapy [OAT] or high coverage needle/syringe programs [HCNSP]). We
evaluated the number of direct-acting antiviral (DAA) treatments needed from 2019 to achieve elimination
targets (80% incidence reduction, 65% mortality reduction by 2030) with: (a) DAAs alone, (b) DAAs plus scale-
up of OAT+HCNSP (up to 50% coverage of OAT and HCNSP separately, producing 25% of PWID receiving
both), (c) DAAs plus CAP scale-up to 50%. Scenarios examined the number of DAAs required if prioritized to
current PWID or provided regardless of current injection status, and impact of harm reduction interruptions.
Results: Modeling suggests among ~30,000 current and former PWID in Tijuana, 16,160 (95%CI:
12,770–21,610) have chronic HCV. DAA scale-up can achieve the incidence target, requiring 770 treatments/
year (95%CI: 640–970) if prioritized to current PWID. 40% fewer DAAs are required with OAT+HCNSP scale-up
to 50% among PWID, whereas more are required with involuntary CAP scale-up. Both targets can only be
achieved through treating both current and former PWID (1,710 treatments/year), and impact is reduced with
harm reduction interruptions.
Conclusions: Elimination targets are achievable in Tijuana through scale-up of harm reduction and DAA therapy,
whereas involuntary CAP and harm reduction interruptions hamper elimination.
Introduction
Hepatitis C virus (HCV) is a blood-borne infection which, if
untreated, can result in cirrhosis, liver cancer, and death. Of the esti-
mated 71 million chronic HCV infections globally, 80% occur in low to
middle income countries (LMIC) (Graham & Swan, 2015;
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Polaris Observatory, 2017). Globally, people who inject drugs (PWID)
are a main group at risk for HCV transmission, with an estimated 52%
of all PWID having a history of HCV infection (Degenhardt et al., 2017).
In addition, an estimated 43% of incident HCV infections could be
prevented from 2018–2030 if the risks of unsafe injecting practices
were removed (Trickey et al., 2019). In 2016, in an effort to focus re-
sources on reducing the high global burden of HCV and aim for global
elimination, the World Health Organization (WHO) set elimination
targets to be achieved by 2030 (WHO, 2016). These elimination targets
include an 80% reduction in HCV incidence and 65% reduction in HCV-
related mortality in 2030 compared to 2015 (WHO, 2016). In 2019,
Mexico became the first country in Latin America to launch an HCV
elimination strategy, with the first phase including purchase of 12,500
direct-acting antiviral (DAA) treatments, among an estimated
450–550,000 people with HCV infection in Mexico (Ochoa, 2019;
Secretaría de Salud, 2019). Yet the intervention scale-up required to
achieve the WHO elimination targets among PWID is unknown, parti-
cularly in settings with very high HCV prevalence and limited harm
reduction as in Mexico.
Tijuana, Mexico, a border city with the United States, is situated on
a major drug trafficking route. Within Mexico, Tijuana has had the
highest rates of illicit drug use and the most recent estimate suggests
that approximately 10,000 current PWID reside there (Magis-
Rodriguez et al., 2005). HCV is highly prevalent among PWID in
Mexico, with HCV seroprevalence being reported among PWID as high
as 92% in Ciudad Juarez and 79% in San Luis Rio Colorado (Fleiz-
Bautista et al., 2019). In Tijuana, seroprevalence exceeds 90% (Fleiz-
Bautista et al., 2019; White et al., 2007). Despite this, access to harm
reduction is minimal. After a brief increase in needle and syringe ex-
change program (NSP) services resulting from the Global Fund support
in 2011–2013, withdrawal of this funder has severely limited NSP
provision (Bórquez et al., 2019; Cepeda et al., 2019) and there is no
access to High Coverage NSP [HCNSP] (as defined as receiving one or
more sterile needles/syringes for each injection (Platt et al., 2018)) in
Tijuana. These services are critical given the evidence they reduce re-
cent HIV transmission (Aspinall et al., 2014), and could reduce HCV
transmission, particularly if provided in combination with opiate ago-
nist therapy (OAT) (Platt et al., 2018). Access to evidence-based OAT
among PWID is <5% (Robertson et al., 2014). Instead, beginning in
2014, government funds in Tijuana were allocated to compulsory drug
abstinence programs (CAP), which remain the main type of drug re-
habilitation program available (Juridicción Sanitaria, 2016). In Ti-
juana, CAPs entail involuntary physical restraint of individuals in non-
Fig. 1. Model schematics showing (A) HCV disease progression by liver disease states and (B) stratification by harm reduction interventions. PWID: People who inject
drugs; OAT: Opiate agonist therapy; HCNSP: High coverage needle/syringe exchange program (receiving≥1 sterile syringes per injection). *PWID exiting the model
due to death; ΔCurrent PWID transitioning to former PWID model, resulting from permanent cessation.
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3
medically supervised centers for approximately 3–6 months, with non-
evidence-based detoxification and abstinence interventions
(Rafful et al., 2019). PWID who had been brought involuntarily by
friends/family or police to CAP were more likely to engage in receptive
syringe sharing, which if this association is causal, could mean in-
voluntary exposure to CAPs fuel HIV transmission, and therefore could
serve to disseminate HCV and hamper elimination progress
(Bórquez et al., 2018).
Previous mathematical models of HCV transmission amongst PWID
found modest scale-up of HCV antiviral treatment, especially coupled
with harm reduction interventions such as OAT and HCNSP could be
used as prevention (Martin, Vickerman et al., 2013; Martin, Hickman,
Hutchinson, Goldberg & Vickerman, 2013). Yet only a few modeling
studies have examined what combination intervention scale-up is re-
quired to achieve the WHO elimination targets among PWID, and these
were limited to high income settings (Fraser et al., 2018). We used
dynamic modeling to determine the level of combination intervention
scale-up necessary to achieve WHO hepatitis C virus elimination goals
of 80% incidence reduction and 65% mortality reduction by 2030
among PWID in Tijuana, and to assess the potential impact of in-
voluntary CAP expansion or interruptions to harm reduction services.
Methods
Mathematical model
We constructed a dynamic, deterministic model of HCV transmis-
sion and progression among current and former (permanently cessated)
PWID. We assumed transmission only occurs among current PWID, but
continue to track HCV disease progression and mortality among former
PWID. We used this model to evaluate changes in prevalence, in-
cidence, and mortality with varying levels of scale-up of DAA treatment
and harm reduction interventions (Fig. 1). We modeled an open po-
pulation where individuals continually enter due to initiation of drug
use and exit the model due to death. Additionally, we assumed random
mixing among PWID and that PWID continuously transition between
evidence-based harm reduction intervention compartments: (a) no in-
tervention, (b) OAT only, (c) HCNSP only, and (d) OAT + HCNSP si-
multaneously. A proportion of PWID may become chronically infected
with HCV, with their risk being proportional to the background pre-
valence of disease and to their intervention exposure. Those with
chronic infection who remain untreated can progress to decompensated
cirrhosis (DC), hepatocellular carcinoma (HCC), and death. Individuals
with chronic infection can receive DAAs. For those who received DAAs,
a proportion may fail treatment and remain chronically infected, and
progress through the natural history of disease stages. PWID who are
successfully treated, progress to the previously infected compartment,
where they are at risk of re-infection. After permanent injecting ces-
sation, former PWID are tracked in our model for disease progression.
For the baseline scenario, we assumed that PWID with DC or HCC are
not provided DAA treatment as this is unlikely to occur currently given
health services in Tijuana. We assumed no coverage of HCV treatment
at baseline given the lack of availability in Mexico. At baseline, we also
assume no coverage of harm reduction (OAT or HCNSP), as <5% of
PWID in Tijuana report recent access to OAT, and there is no access to
HCNSP. For an alternative scenario analysis, we redefine the OAT
compartment to represent involuntary receipt of CAP, and parameterize
the relative risks accordingly to examine the impact of scale-up of CAP
instead of OAT. Analyses were conducted in Matlab version R2018b
(The Mathworks, Inc., Natick, MA).
Model parameterization
The model was parameterized to Tijuana, Mexico, with an estimated
10,000 current PWID (Magis-Rodriguez et al., 2005). Model parameters
were obtained from published literature and data from cross-sectional
and longitudinal cohorts of PWID in Tijuana (Table 1). HCV ser-
oprevalence (90%) was obtained from PWID recruited from drug con-
sumption sites in Tijuana between 2017 and 18 (Fleiz-Bautista et al.,
2019). Similar to other modeling analyses (Martin, Hickman et al.,
2013), we estimate chronic prevalence from seroprevalence, based on a
26% spontaneous clearance rate (95% CI: 0.22–0.30) from a systematic
review of longitudinal studies (Micallef, Kaldor & Dore, 2006), con-
sistent with other studies evaluating spontaneous clearance among
PWID (Kaberg, Naver, Hammarberg & Weiland, 2018) as well as region-
specific viraemic rates (74% for Latin America)
(Petruzziello, Marigliano, Loquercio, Cozzolino & Cacciapuoti, 2016).
Data including proportion of individuals accessing harm reduction in-
terventions (OAT, HCNSP), the average duration of injecting, and PWID
mortality rate were obtained from the El Cuete IV study in Tijuana
(Bórquez et al., 2018; Robertson et al., 2014; West et al., 2019).
Average duration of injecting by sex was obtained from the El Cuete IV
study and weighted by the distribution of PWID in Tijuana by sex (85%
males, 15% females, (Strathdee et al., 2008), as women were over-
sampled in El Cuete IV.
Intervention effect estimates: HCV DAA sustained virological response
(SVR) rates (approximately 95%) were obtained from published data
for PWID (Dore et al., 2016; Grebely et al., 2018). Effectiveness of
evidence-based OAT and HCNSP (defined as receiving one or more
sterile syringe per each injection) on reducing HCV acquisition was
obtained from a Cochrane systematic review and meta-analysis, with
OAT reducing the risk of HCV transmission by 50% (sampled from the
95% confidence interval (95%CI) of the relative risk (RR): 0.40–0.63),
and with HCNSP reducing the risk of HCV transmission by 23% (sam-
pled from the 95%CI of the RR 0.38–1.54) (Platt et al., 2018). In
combination, both HCNSP and OAT reduce the risk of acquiring HCV by
an estimated 71% (sampled from the 95%CI of the RR: 0.13–0.65)
(Platt et al., 2018). Data from El Cuete IV cohort among PWID in Ti-
juana indicate that, compared to PWID never exposed to involuntary
CAP, PWID with a history of involuntary CAP had an elevated relative
risk of recent receptive syringe sharing (RR 1.14 [95%CI: 1.00–1.30])
(Bórquez et al., 2018). We note that it is unclear from the epidemio-
logical data whether this elevation in syringe sharing occurs during
and/or after CAP exposure, or whether this association is truly causal.
However, evidence from other custodial settings (such as prisons)
where injecting drug use is prohibited indicates that although a lower
proportion of PWID continue to inject drugs while detained, injecting
risk is greatly enhanced due to elevated rates of syringe sharing
(Cunningham et al., 2018; Dolan et al., 2010). Accordingly, we im-
plemented the effect of CAP exposure in the model by assuming a 14%
increase (varying from 0 to 30%) in receptive syringe sharing among
PWID while in CAP. As such, our model neglects any potential negative
effects of syringe sharing on CAP after release.
Model calibration
To account for uncertainty in these model parameters, we sampled
1000 parameter sets from each parameter's associated uncertainty dis-
tribution (Table 1). For each parameter set, the model was calibrated to
HCV chronic prevalence among PWID in Tijuana in 2018, through
varying the HCV transmission rate (calibrated fits shown in Supple-
mentary Fig. S1). Since historic estimates show stable HCV prevalence
among PWID in Tijuana (Fleiz-Bautista et al., 2019; Frost et al., 2006;
White et al., 2007), we assumed HCV is at steady-state. We then cali-
brated fixed recruitment rates onto OAT and HCNSP starting in 2019
required to achieve scale-up to 20%, 40%, and 50% coverage by 2030
of each intervention among PWID for each intervention scenario (pro-
ducing 10%, 20%, and 25% of PWID receiving both OAT and HCNSP).
Model calibration was achieved by minimizing the least squares fit to
the prevalence data using a global optimization solver (lsqnonlin with
multistart in MATLAB).
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Intervention scenarios
We evaluated various strategies to achieve the previously-refer-
enced WHO HCV elimination goals. We examined the impact on in-
cidence, chronic prevalence, and HCV-related mortality of the fol-
lowing intervention scenarios:
1) Status quo: no treatment or harm reduction.
2) DAAs only: DAA treatment scale-up only beginning in 2019 to
achieve the elimination goals.
3) DAAs combined with evidence-based harm reduction: DAA treat-
ment scale-up in combination with scaled-up OAT+HCNSP from
2019 to reach 20%, 40%, or 50% coverage levels of each inter-
vention among PWID by 2030 (producing 10%, 20%, and 25% of
PWID receiving both OAT and HCNSP). Supplementary Fig. S2
shows coverage scale-up over time.
4) DAAs combined with involuntary CAP: DAA treatment scale-up in
combination with scaled-up CAP to 50% among PWID beginning in
2019.
Additionally, to evaluate the potential impact of interruptions in
harm reduction coverage as historically observed, we examined the
impact of scale-up of combination prevention required to achieve the
incidence target (DAAs and 50% OAT+HCNSP among PWID) but in-
terruption/removal of harm reduction from 2025–2030.
Sensitivity analyses
Due to parameter uncertainty, we performed sensitivity analyses
examining the impact on numbers of treatments (inclusive of retreat-
ments of reinfection) required to achieve both elimination goals if DAAs
are allocated to both current and former PWID with the following
scenarios: lower or higher number of current PWID (5000 or 15,000
compared to 10,000 at baseline), lower chronic prevalence among
current PWID (50%, compared to 67% at baseline), lower SVR (90% vs
95% at baseline), and differing injecting duration (5 years or 25 years,
compared to 17.5 at baseline).
RESULTS
Model calibration
The calibrated model estimated 10,000 current PWID, with an as-
sociated 19,500 former PWID, (95% CI: 12,700–30,200) in Tijuana.
Among the approximately 30,000 individuals with a history of injection
drug use (IDU), we estimated there were 16,160 (95% CI:
12,770–21,610) chronic HCV infections in 2019. In 2019, HCV in-
cidence among PWID was estimated to be 20 per 100 person years
(/100py) (95% CI: 14–29/100py), equating to 650 new infections per
year (95% CI: 510–850). An estimated 430 current PWID (95% CI:
310–560) and 1350 former PWID (95% CI: 910–1970) had decom-
pensated cirrhosis and approximately 100 current PWID (95% CI:
60–160) and 280 former PWID (95% CI: 150–500) had hepatocellular
carcinoma. Among both current and former PWID, there were an esti-
mated 330 (95% CI: 250–440) HCV-related deaths in 2019.
WHO goal: achieving 80% incidence reduction among PWID by 2030
Combination intervention strategies needed to achieve 80% in-
cidence reduction (from 20/100py to 4/100py) in Tijuana among PWID
by 2030 are shown in Fig. 2. Without any DAA treatment, harm re-
duction alone was unable to achieve the 80% incidence target (Sup-
plementary Figs. S3 and S4). If DAAs were prioritized to PWID, DAAs
alone, at a median rate of 770 annually [95% CI: 640–970] (equivalent
to 11% of chronic infections among PWID being treated the first year)
could achieve the HCV incidence target by 2030. Moderate scale-up of
OAT+HCNSP to coverage levels of 20% or 40% among PWID, in ad-
dition to DAA scale-up, reduced the annual number DAAs needed to
670 PWID annually (95%CI: 540–850) or 540 PWID annually (95% CI:
410–750), respectively. Scaling up OAT+HCNSP to 50% coverage
among PWID reduced the DAAs required by 40% (460 PWID annually
[95% CI: 310–690]). Conversely, if involuntary exposure to CAP were
scaled-up to 50% coverage among PWID, 7% more DAAs would be
required compared to DAAs alone because of the increase in syringe
sharing (and therefore HCV) associated with CAP (830 annually [95%
CI: 670–1080]).
If DAAs were provided without regard to injecting status, nearly
double the DAA treatment numbers would be required to achieve the
incidence target, compared to if DAAs were prioritized to current PWID
(1480/year [95%CI: 1150–2150], Fig. 2). Without DAA prioritization,
combination scale-up of OAT+HCNSP to current PWID could sub-
stantially reduce the DAAs required by 30% if harm reduction was
scaled-up to 50% coverage among current PWID. As before, scale-up of
CAP to 50% coverage would require more DAAs to achieve the WHO
target (Fig. 2).
Achieving both 80% incidence reduction and 65% HCV-related mortality
reduction by 2030
To achieve the 65% HCV-related mortality reduction, total HCV-
related deaths among both current and former PWID would need to
decrease from an estimated 330/year in 2018 to <110/year by 2030.
More DAAs would be required to reach both WHO targets compared to
the incidence target alone (Fig. 3). To achieve the HCV-related mor-
tality target, treatment must also be provided to former PWID. Even if
current PWID were treated each year, HCV-related mortality could only
be reduced by a maximum of 55% by 2030. If DAAs were provided to
current and former PWID, approximately 1710 (95%CI: 1310–2430)
would need to be treated annually to reach both targets (13% greater
than the incidence target). Scaling up evidence-based harm reduction
reduces DAAs required compared to giving DAAs only; scaled-up
OAT+HCNSP to 50% coverage among PWID requires 15% fewer
treatments per year to reach both targets (1450 [95%CI: 1090–2060]).
Impact of interruptions in harm reduction coverage
Even if combination intervention scale-up is achieved from
2020–2025, HCV incidence can rebound if harm reduction
(OAT+HCNSP) availability is stopped at 2025 increasing by a mean
relative 18% from 2025–2030 (Fig. 4).
Sensitivity analysis
Sensitivity analyses evaluating the numbers of DAAs required to
achieve both elimination goals when allocated randomly are shown for
various scenarios in Supplementary Fig. S5. For both elimination goals,
more treatments (median to reach incidence: 1590 [95%CI:
1230–2300]; median to reach mortality: 1870 [95%CI: 1420–2700])
were required with a lower SVR rate (90%), and more (median to reach
incidence: 1850 [95%CI: 1350–2910]; median to reach mortality: 2170
[95%CI: 1560–3310]) were required when the average duration of in-
jection was short (5 years). Fewer treatments were also needed if the
baseline chronic prevalence was 50% (median to reach incidence: 970
[95%CI: 800–1320]; median to reach mortality: 1150 [95%CI:
920–1610]) and the average duration of injection was longer (25 years;
median to reach incidence: 600 [95%CI: 440–910]; median to reach
mortality: 720 [95%CI: 520–1070]). Estimates of numbers of treat-
ments required scaled linearly with analyses assuming greater (50%
more; median: 2220–2570) or fewer (50% fewer; median: 740–860)
PWID.
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Discussion
There is a high burden of HCV among people with a history of IDU
in Tijuana, Mexico, where harm reduction and HCV treatment access is
low. Our modeling indicates that even in very high burden settings such
as Tijuana, HCV elimination could be achieved provided the
forthcoming DAAs are widely available, scaled-up among both current
and former PWID, and there is concomitant scale-up of harm reduction
services. The incidence target could be achieved through treating ap-
proximately 770 (95%CI: 640–970) current PWID annually, but 40%
fewer would be required if combination harm reduction is scaled-up
among 50% of PWID. If DAAs were allocated at the same level needed
Fig. 2. Annual DAA treatment numbers (B) required (with or without combination scale-up) to achieve an 80% incidence reduction among PWID by 2030 in Tijuana,
Mexico, if treatment is prioritized to current PWID or allocated to current and former PWID. Scenarios examine combination scale-up of DAAs with evidence-based
harm reduction (OAT + HCNSP) or involuntary exposure to compulsory drug abstinence programs (CAP). DAAs: HCV direct-acting antiviral treatment; OAT: Opiate
agonist therapy; HCNSP: High coverage needle/syringe exchange program (receiving≥1 sterile syringes per injection). (For interpretation of the references to colour
in this figure legend, the reader is referred to the web version of this article.)
Fig. 3. Annual DAA treatment numbers re-
quired (with or without combination scale-up)
to achieve both WHO targets (80% incidence
reduction and 65% reduction in HCV-related
mortality) by 2030 in Tijuana, Mexico, if
treatment is prioritized to current PWID or al-
located to current and former PWID. Scenarios
examine combination scale-up of DAAs with
evidence-based harm reduction (opiate agonist
therapy and high coverage needle/syringe
programs, OAT + HCNSP) or involuntary ex-
posure to compulsory drug abstinence pro-
grams (CAP). DAAs: HCV direct-acting anti-
viral treatment; OAT: Opiate agonist therapy;
HCNSP: High coverage needle/syringe ex-
change program (receiving ≥1 sterile syringes
per injection). ****Treating only current PWID
cannot achieve the 65% mortality goal by
2030. (For interpretation of the references to
colour in this figure legend, the reader is re-
ferred to the web version of this article.)
L.K. Marquez, et al. International Journal of Drug Policy xxx (xxxx) xxxx
6
to achieve the WHO elimination goals using treatment alone, the goals
could be met earlier if combination harm reduction is scaled-up. Over
double the number of treatments (median 1710) would be required to
achieve both the incidence and mortality targets, and these would need
to reach both current and former PWID. Allocation of the currently
purchased 12,500 DAAs across Mexico is unclear, but if allocated in
proportion to estimated burden, then approximately 355–600 total
treatments would be allocated to Tijuana, indicating treatment invest-
ment needs to be increased for WHO elimination. However, the in-
cidence target may be achievable with expansion of harm reduction. As
such, our findings highlight the critical role harm reduction can play in
achieving elimination and reducing the number of DAAs required, and
that sustained harm reduction is important to maintaining elimination.
Furthermore, there are multiple sites in Mexico with concentrated HCV
epidemics among PWID, including in other U.S. border cities of Ciudad
Juarez and San Luis Rio Colorado (Fleiz-Bautista et al., 2019), further
highlighting the need for DAAs to be allocated to the PWID within these
communities to halt transmission.
There are numerous challenges which curtail the possibility of
achieving HCV elimination in Tijuana. Despite indication that HCV
treatment will become available under the Mexican public health care
system, and that it will be available or PWID, DAAS are not currently
available for PWID in Tijuana. Additionally, even if technically avail-
able, many PWID do not access or receive basic health care
(Davidson et al., 2012; Smith et al., 2016), in part due to negative ex-
periences and stigma (Biancarelli et al., 2019; von Hippel, Brener &
Horwitz, 2018), both internalized and expressed by healthcare provi-
ders (Brener et al., 2019; Paquette, Syvertsen & Pollini, 2018). Ad-
ditionally, PWID often lack the documentation required to register for
Mexico's national health care system. Compounding this lack of access
is also a lack of awareness of HCV. Estimates of the proportion of HCV-
infected individuals who are diagnosed in Tijuana are unknown, but in
a recent cross-sectional survey among PWID in treatment centers in
Tijuana, despite the vast majority of PWID harboring HCV infection,
only 25% of all respondents self-reported having ever been diagnosed
with HCV, and none had received treatment (unpublished data from
Fleiz-Bautista et al., 2019). However, once diagnosed and initiated on
treatment, other studies have found high HCV treatment adherence
rates among PWID, which supports feasibility of implementing these
interventions in Tijuana (Dore et al., 2016).
In addition to barriers to treatment scale-up, expansion of evidence-
based harm reduction is challenging in Tijuana. Existing OAT provision
is expensive, and unaffordable for most PWID (Burgos et al., 2018).
Capacity is also a considerable issue, as OAT is only offered by a few
providers, so expansion of providers would be required. As mentioned,
government funding has been provided for CAPs, which based on our
model should be reoriented towards evidence-based treatment, in-
cluding OAT provision to enhance HCV elimination strategies. Expan-
sion in the quantity of HCNSPs and their provision is also urgently
needed, particularly as the withdrawal of the Global Fund in late 2013
resulted in a dramatic reduction in the number of syringes and ancillary
harm reduction components provided, as well as the geographical scope
of the service, leading to increases in syringe sharing (Bórquez et al.,
2019). The intermittent and fluctuating provision of harm reduction
and recent cut to harm reduction funding in Mexico will hamper efforts
to control HCV (Lopez, 2019); our simulations indicate that even if
scaled-up to achieve WHO targets, removal of these programs after
2030 will allow HCV infections to rebound to their pre-treatment levels.
We recognize that within government administrations, there is un-
certainty in securing, directing, and continuing funding for such pro-
grams, spanning all levels from municipal, state, to federal, particularly
with frequent turnover of elected officials. Our analyses support the
need to provide long-term funding opportunities as to prevent a re-
bound in HCV transmission both before and after HCV elimination goals
have been met. Importantly, there are additional benefits of im-
plementing the proposed harm reduction strategies which are not
Fig. 4. Future projections of HCV incidence among PWID in Tijuana with: status quo scenario, combination harm reduction elimination scenario (DAAs plus
OAT + HCNSP at 50% coverage), and combination intervention but harm reduction removal in 2025. Lines present mean values from 1000 simulations. Dashed lines
show 2.5 and 97.5% centile predictions from the baseline scenario. DAA: Direct-acting antiviral treatment; OAT: Opiate agonist therapy; HCNSP: Needle/syringe
exchange program. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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represented in this model which might have a broader impact on the
health of the PWID community in Tijuana. For example, improved harm
reduction coverage could additionally reduce HIV transmission
(Aspinall et al., 2014), fatal overdoses (Sordo et al., 2017) and re-
incarceration (Larney, Toson, Burns & Dolan, 2012), which itself is
associated with HIV and HCV risk (Stone et al., 2018).
Strengths and limitations
To our knowledge this is the first modeling analysis to project the
level of combination interventions required to achieve the WHO HCV
global elimination goals among PWID in a low-middle income setting.
Other studies have examined country-level elimination strategies, such
as in Pakistan, which also highlight the benefit of prioritization of PWID
and of concomitant scale-up of harm reduction on achieving elimina-
tion (Lim et al., 2018). Our results also support findings from other
studies that combination harm reduction and treatment strategies are a
key component of HCV epidemic control (Gountas et al., 2017;
Heffernan, Cooke, Nayagam, Thursz & Hallett, 2019). Additionally, our
results support literature showing that scaling-up harm reduction in-
terventions reduces the number of treatments required and is cost-ef-
fective in the United States (Fraser et al., 2018). Finally, this analysis
supports our previous modeling work indicating that scale-up of in-
voluntary exposure to CAP could increase infectious diseases among
PWID, such as HIV (Bórquez et al., 2018).
Our modeling study has a number of limitations, most notably re-
lated to uncertainty in parameterization. To account for these, we in-
corporated these uncertainties in our analysis and performed additional
sensitivity analyses. First, there is substantial uncertainty in the number
of PWID in Tijuana, with the estimate of 10,000 PWID arising from a
Centro Nacional para la Prevención y Control del VIH/SIDA (CENSIDA)
cross-sectional survey of 35 zones in Tijuana (Magis-Rodriguez et al.,
2005). Our sensitivity analyses indicate uncertainty could strongly
impact the number of DAAs needed. More robust, current estimates of
PWID population sizes in Tijuana would help improve intervention
planning and resource allocation.
Second, there is always considerable uncertainty in the average
duration of injecting until final cessation as injecting drug use is a
chronic relapsing condition. Cohort estimates of average duration of
injection are often used to infer average time to cessation, yet these data
are both right censored (participants have not cessated yet) and left
censored (people who inject for a very brief period of time are unlikely
to be captured by the cohort). As such, we used Tijuana data to inform
this estimate but account for wide uncertainty in this parameter within
our analyses. More generally, we note that our analysis characterizes
the PWID population between those who have permanently cessated
from injecting and those who have not, and as such do not explicitly
simulate periods of temporary cessation. Thus, the current PWID
prioritization strategies we examine incorporate prioritization to PWID
who may be in a period of temporary cessation (such as those receiving
OAT), but who are at high risk of relapse, and therefore future trans-
mission.
Third, as HCV treatment is unavailable in Tijuana, we were unable
to obtain local estimates of SVR rates and relied on estimates from other
populations. However, studies of PWID indicate SVR among those with
a history of IDU or who continue to inject after treatment, are high and
exceed 90% (Grebely et al., 2018).
Fourth, we assumed exposure to involuntary CAP is causally asso-
ciated with increased receptive syringe sharing while exposed to CAP,
however causality has not been established and even if causal it is
unclear when syringe sharing is elevated. It is possible that PWID who
are involuntarily brought to CAPs may represent a population with
higher baseline injecting risk. Alternatively, the observed increased
odds in syringe sharing could potentially result from poor mental health
and consequences of diminished self-care following physical or psy-
chological abuse occurring in CAPs (Bórquez et al., 2018). Additionally,
it is possible individuals who relapse after CAP release may share more
to avoid being caught in trying to obtain clean syringes. Further, even if
exposure to CAP causes syringe sharing it is unclear whether risk is
elevated during and/or after exposure. Indeed, recent incarceration has
been associated with elevated HIV and HCV incidence, but there is
evidence this effect persists long-term (Stone et al., 2018). As duration
in CAP is relatively short (6–12 months) compared to an overall in-
jecting career, if there is a long-term excess risk associated with CAP
these would not be included in our results, and would mean CAP has
even more of a negative effect than we predict. Future work examining
causal pathways and periods of heightened risk associated with CAP is
warranted.
Furthermore, we neglected to account for HIV among PWID in
Tijuana in our model as previous studies have shown it to be relatively
low (3–7%) compared to HCV prevalence (Fleiz-Bautista et al., 2019;
Strathdee et al., 2008). HIV infection would act as a competing risk for
death; however, the same intensity of interventions would be required
to reach the same relative reduction in HCV related mortality regardless
of HIV status.
Finally, our analyses explored DAA provision to PWID with chronic
infection, as the current published strategy highlights PWID as a
priority population, and does not restrict by disease stage. Yet, we re-
cognize that given the current health system reform in Mexico, the
prioritization and allocation of treatment may change in the future,
which would merit further modeling to assess the population impact
and cost-effectiveness of these strategies. As the current strategy focuses
highlights PWID and prisoners (many of whom are PWID) as priority
populations, strategies to improve case finding and linkage to care
among these groups will be an important focus. Future studies should
examine these issues in further detail.
Conclusion
In conclusion, WHO global elimination goals can be achieved by
2030 in Tijuana, Mexico, through combination scale-up of evidence-
based harm reduction and DAA treatment. Access to affordable HCV
treatment and sustained evidence-based harm reduction is critical to
achieving these goals, and existing compulsory abstinence programs
could hamper elimination efforts.
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